Sarah Bedell, MD
Obstetrics & Gynecology · Miami, FLNPI 1902149255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 38.9% of the total. Reporting peaked in 2020 at $353 and has fallen 90.5% since, to $34 in 2025.
Across 38 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$420
- Astellas Pharma US Inc$146
- Sage Therapeutics, LLC$137
- Mylan Pharmaceuticals Inc.$79
- Biotissue Holdings Inc.$78
- Daiichi Sankyo Inc.$34
- plus $184 from 9 others
Across 46 payments — averaging $30,269 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Incyte Corporation$323K
What the payments were for
- Food & beverage$98791%
- Education$929%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $420 |
| Astellas Pharma US Inc | 4 | $146 |
| Sage Therapeutics, LLC | 2 | $137 |
| Mylan Pharmaceuticals Inc. | 4 | $79 |
| Biotissue Holdings Inc. | 1 | $78 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Myovant Sciences Inc. | 1 | $29 |
| Mayne Pharma Commercial LLC | 1 | $28 |
| Bayer | 1 | $24 |
| Exeltis, USA Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Mycovia Pharmaceuticals, Inc. | 1 | $20 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Lupin Inc. | 1 | $15 |
| Meditrina | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,079 in reported general payments places this provider in the 55th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 82 | $6,543 |
| ProgesteroneProgesterone, Micronized | 35 | $1,559 |
| Estradiol (Twice Weekly)Estradiol | 14 | $1,477 |
| Clobetasol Propionate | 38 | $1,308 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Miami
- Youssef MouhayarMiami$162K
- Rebeca MartinezMiami$108K
- Jason JamesMiami$97K
- Peter KhamvongsaMiami$67K
- Abdulrahman SinnoMiami$67K
- Ingrid ParedesMiami$65K
- Karen Salazar ValdesMiami$29K
- Steven McCarusCelebration$2.3M
- Elliot CazesTampa$725K
- Charles BloomWinter Park$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.